This assumption is valid since the myeloma-enriched regions in bone marrow are well vascularized and the diffusion of small molecule drugs is significantly faster comparing with either typical cell behaviors such as migration, proliferation, and apoptosis, or comparing with the diffusion of SDF-1. The gene discussed is CXCL12; the disease is plasma cell myeloma.